Report LibraryAll Reports
Hormone Refractory Prostate Cancer Therapies, Phase III & Pivotal Phase II
Retail Price: $1,800.00
August 16, 2017Ongoing industry-sponsored Phase III (including II/III) and pivotal Phase II HRPC trials. Excludes trials focused on biosimilars, generics, supportive care, metastases (to brain, bone, etc.) and trials that began prior to January 1, 2012.
Trialscape is a powerful visual analysis tool derived from the comprehensive clinical trials intelligence in Citeline’s Trialtrove. Each Trialscape map displays the current and future competitive landscape of pharmaceutical clinical trials in a specific area of research. The Trialscape solution provides graphical representation of pharmaceutical clinical trial timelines in support of strategic decisions in drug development, clinical operations and marketing. In addition to the Trialscape maps available for purchase here, Citeline also offers bundled pricing for all maps in a therapeutic area. If your interest is in areas beyond the current inventory, our analysts will work with you to create a custom deliverable. Please contact email@example.com for more information.
|Disease Group Covered:||Oncology|